Role of inducible nitric oxide synthase expression in aberrant crypt foci-adenoma-carcinoma sequence

Table 1 iNOS expression in normal mucosa-ACF-adenoma-carcinoma sequence

	iNOS expression			Total
	Strong	Intermediate	Weak or absent
Normal mucosa	3	6	21	30
Nonhyperplastic ACF	6	8	16	30
Hyperplastic ACF	8	10	12	30
Dysplastic ACF	26	2	2	30
Adenoma	24	4	2	30
Carcinoma	41	10	9	60

Table 2 Changes in AI, PCNA-LI, and MVD in ACF-adenoma-carcinoma sequence (^¯x± s)

	n	AI(%)	PCNA-LI (%)	MVD (MVD/0.74mm2)
Normal mucosa	30	0.21 ± 0.13	12.1 ± 2.48	50 ± 10.3
Nonhyperplastic ACF	30	0.28 ± 0.16	14.7 ± 2.47	52 ± 10.6
Hyperplastic ACF	30	0.73 ± 0.37ab	27.3 ± 2.80ab	55 ± 11.5
Dysplastic ACF	30	0.61 ± 0.35abc	40.3 ± 3.11abd	70 ± 13.2abd
Adenoma	30	0.58 ± 0.25abc	45.4 ± 3.24abd	80 ± 14.7abde
Carcinoma	60	0.49 ± 0.43abde	52.2 ± 3.17abdf	95 ± 13.3abdf

^aP < 0.01, vs normal mucosa;

^bP < 0.01, vs nonhyperplastic ACF;

^cP < 0.05, vs hyperplastic ACF;

^dP < 0.01, vs Hyperplastic ACF;^eP < 0.05, vs dysplastic ACF;

^fP < 0.01, vs dysplastic ACF.